Led by former Novartis executive Emanuele Ostuni, the startup has a prostate cancer medicine advancing into early clinical ...

Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but ...

Novartis moves to block cancer drug generic in US ...

Ninety percent of parents, expectant parents said they'd want to know early about SMA, and 80% said not screening newborns ...

Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer in a late-stage study, sending the biotech firm's shares surging to a record ...

People in 15 regions across the U.S. will soon benefit from the American Heart Association’s Cardiovascular-Kidney-Metabolic Health Initiative™, designed to improve treatment of the interconnected ...

US President Trump imposed 200% tariff on pharmaceuticals affecting US drug prices and supply chain, but analysts say it may ...

The health sector sees significant developments as Edwards Lifesciences raises sales forecast due to strong demand for heart devices, while Bavarian Nordic enters potential takeover talks. Moreover, ...

Matchpoint Therapeutics Inc. and Novartis AG have entered into an exclusive option and license agreement to develop and commercialize oral covalent inhibitors targeting a transcription factor linked ...

Matchpoint Therapeutics has entered into an exclusive option and license agreement with Novartis to develop and commercialize oral covalent inhibitors.

Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several ...